AGP
OCUL icon

Artia Global Partners’s Ocular Therapeutix OCUL Stock Holding History

Artia Global Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-85,200
Closed -$1.03M – 55
2025
Q4 		$1.03M Buy
+85,200
New +$1.03M 0.15% 48

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Artia Global Partners's OCUL Position: Q1 2026 in Review

Artia Global Partners sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 141,061 shares — an estimated $1.71M sold.

Artia Global Partners first reported a position in OCUL in Q4 2023 and held it in 5 quarters. The position peaked at $6.59M in Q1 2024. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Artia Global Partners reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • Artia Global Partners sold 141,061 Ocular Therapeutix shares in Q1 2026, an estimated $1.71M.
  • Artia Global Partners first reported a position in Ocular Therapeutix in Q4 2023 and held it in 5 quarters.
  • Artia Global Partners's Ocular Therapeutix position peaked at $6.59M in Q1 2024.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Artia Global Partners's 13F filing for Q1 2026, filed 15 May 2026.